Abstract:Abstract We present a rare diagnosis in a 41-year-old man referred urgently from the infectious diseases team with a 3-week history of extensive itchy and painful mucocutaneous blistering and ulceration. This initially affected his hands, spreading to involve his limbs and trunk. His oral and genital mucosae were similarly affected. He reported lethargy and weight loss secondary to reduced oral intake but was otherwise systemically well. He had hypertension managed with amlodipine but he had not recently taken any other medications or supplements. He had emigrated to the UK from Ghana 6 months earlier and no contacts were similarly affected. Examination revealed multiple tense vesicles and bullae with crusted erosions scattered across his trunk and limbs on a background of urticated erythema involving approximately 40% of his body surface area. Haemorrhagic bullae were present on his tongue, his labial and buccal mucosa, and his genital mucosa. He had an extensive infection screen. Of note, viral polymerase chain reaction of vesicular fluid was negative and he was noted to have negative varicella zoster virus (VZV) IgG, in keeping with his history of never previously having chickenpox. Histopathology demonstrated subepidermal blistering with neutrophils and a neutrophil-rich superficial perivascular inflammatory infiltrate and small collections of neutrophils in dermal papillae with incipient clefting. Direct immunofluorescence showed linear deposition of IgG and C3 along the basement membrane zone localizing to the base on salt-split skin. Enzyme-linked immunosorbent assay to collagen VII was strongly positive, and it was negative to BP180/230. On the basis of his clinical findings and investigation results, epidermolysis bullosa acquisita (EBA) was diagnosed. After careful consideration and discussion with the patient, the decision was made to delay systemic immunosuppressive treatment until he had completed VZV vaccination. He was initially managed with clobetasol ointment, Trimovate cream (clobetasone butyrate, nystatin and oxytetracycline calcium) and fluticasone mouthwash. He subsequently commenced prednisolone 40 mg daily, with complete resolution of blistering within 1 month, leaving areas of postinflammatory hypopigmentation, scarring and milia. The introduction of dapsone 50 mg daily has enabled him to gradually wean the dose of prednisolone without further flares. EBA is a very rare immunobullous disease characterized by autoantibodies directed against collagen VII. Different clinical phenotypes are recognized, including a mechanobullous phenotype characterized by acral involvement, skin fragility, scarring and milia; an inflammatory phenotype with skin changes resembling pemphigoid; and a mucosal dominant phenotype. His case was complicated by the need to delay systemic immunosuppression to enable VZV vaccination, an important consideration when long-term immunosuppression may be required. Fortunately, our patient has shown an excellent response to dapsone, highlighting the value of this medication in EBA, among other immunobullous diseases.

Bullous Systemic Lupus Erythematosus Successfully Treated With Intravenous Immunoglobulin and Mycophenolate Mofetil

A Case of Bullous Systemic Lupus Erythematousus

Bullous lupus as the first manifestation of systemic lupus erythematosus in the pediatric population: A diagnostic challenge in daily practice

Bullous lupus erythematosus with basement membrane deposits of IgD

Linear IgA bullous dermatosis associated with immunotherapy

[Acquired epidermolysis bullosa with a highly varied clinical picture and successful treatment with mycophenolate mofetil]

Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature

Mycophenolate mofetil therapy for pediatric bullous pemphigoid

DP15 A rare immunobullous diagnosis in a varicella zoster-naive patient

B cell depletion and inhibition in systemic lupus erythematosus

Monoclonal Antibodies for the Management of Cutaneous Lupus Erythematosus: An Update on the Current Treatment Landscape

Biologics in Systemic Lupus Erythematosus: Recent Evolutions and Benefits

Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up

A case of bullous pemphigoid in infancy treated with local corticosteroids

Treatment of Various Ocular Manifestation of Systemic Lupus Erythematosus with Therapeutic Plasma Exchange

A systemic lupus erythematosus patient with persistent elevated conjugated bilirubin as the initial symptom: A case report

Bullous pemphigoid presenting as exfoliative erythroderma

Successful treatment with belimumab for immune thrombocytopenia associated with systemic lupus erythematosus: A report of two cases

AB0525 Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus

Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy